PDE10A and obesity due to melanocortin 4 receptor deficiency: Therefore, PDE10A inhibitors are ideally placed for the treatment of obesity due to their dual ability to suppress hedonic feeding (Nawrocki et al, 2014) and increase energy expenditure.